Morgan Stanley Vbi Vaccines Inc Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.29 - $0.64 $37,039 - $81,743	127,724 Added 74.98%	298,077 $89,000
Q4 2022 Feb 14, 2023	BUY	$0.38 - $22.5 $6,448 - $381,825	16,970 Added 11.06%	170,353 $66,000
Q3 2022 Nov 14, 2022	SELL	$0.73 - $23.4 $275,939 - $8.85 Million	-377,999 Reduced 71.14%	153,383 $109,000
Q2 2022 Oct 27, 2022	SELL	$0.66 - $1.81 $296,522 - $813,189	-449,276 Reduced 45.81%	531,382 $429,000
Q2 2022 Aug 15, 2022	SELL	$0.66 - $1.81 $296,522 - $813,189	-449,276 Reduced 45.81%	531,382 $429,000
Q1 2022 Oct 27, 2022	BUY	$1.27 - $2.47 $570,580 - $1.11 Million	449,276 Added 84.55%	980,658 $1.63 Million
Q1 2022 May 13, 2022	BUY	$1.27 - $2.47 $944,943 - $1.84 Million	744,050 Added 314.47%	980,658 $1.63 Million
Q4 2021 Feb 14, 2022	BUY	$2.21 - $3.22 $157,471 - $229,437	71,254 Added 43.09%	236,608 $553,000
Q3 2021 Nov 15, 2021	BUY	$2.8 - $3.72 $462,991 - $615,116	165,354 New	165,354 $515,000

688K

Ticker VBIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 258,256,992
Market Cap $5.17M
Description
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.